NanoPin Technologies
NanoPin Technologies Inc. is dedicated to advancing infectious disease diagnosis and improving patient care through innovative diagnostic platforms. Their versatile and proprietary technology platform enables rapid, accurate detection of active infectious diseases such as tuberculosis (TB), HIV, and COVID-19 across diverse patient populations. The company's solutions focus on detecting disease-specific biomarkers in blood, distinguishing active from latent infections, and providing tools for global health efforts against infectious diseases. NanoPin's platform is adaptable for future disease markers and outbreak responses, emphasizing a partner-driven approach to impact patient health worldwide.
Industries
Nr. of Employees
small (1-50)
NanoPin Technologies
New Orleans, Louisiana, United States, North America
Products
Serum-based mass spectrometry assay for active tuberculosis
A diagnostic assay that digests patient serum, enriches species-specific peptide biomarkers using antibody capture, and quantifies target peptides by LC-MS/MS to detect active tuberculosis and monitor treatment.
Multiplex serum assay for TB and HIV co-infection (development)
A multiplex diagnostic approach under development that aims to detect markers for tuberculosis and HIV co-infection from serum to inform rapid treatment decisions.
Serum-based mass spectrometry assay for active tuberculosis
A diagnostic assay that digests patient serum, enriches species-specific peptide biomarkers using antibody capture, and quantifies target peptides by LC-MS/MS to detect active tuberculosis and monitor treatment.
Multiplex serum assay for TB and HIV co-infection (development)
A multiplex diagnostic approach under development that aims to detect markers for tuberculosis and HIV co-infection from serum to inform rapid treatment decisions.
Services
Clinical laboratory testing (LDT) for tuberculosis
Provision of laboratory-developed serum-based tests for active tuberculosis performed within a CLIA laboratory environment.
On-site SARS-CoV-2 testing
Appointment-based SARS-CoV-2 testing offered at the company's clinical testing facility with required administrative forms and sample collection procedures.
Analytical workflow development and partnership services
Collaborative development of high-sensitivity analytical workflows and assay transfer for commercial and international deployment.
Clinical laboratory testing (LDT) for tuberculosis
Provision of laboratory-developed serum-based tests for active tuberculosis performed within a CLIA laboratory environment.
On-site SARS-CoV-2 testing
Appointment-based SARS-CoV-2 testing offered at the company's clinical testing facility with required administrative forms and sample collection procedures.
Analytical workflow development and partnership services
Collaborative development of high-sensitivity analytical workflows and assay transfer for commercial and international deployment.
Expertise Areas
- Clinical diagnostics for infectious disease
- Mass spectrometry–based biomarker detection
- Antibody-based enrichment and nanoparticle capture
- Assay development and analytical validation
Key Technologies
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
- Antibody-conjugated nanoparticles
- Magnetic bead-based peptide capture
- Isotope-labeled internal standard peptides